Paediatric drugs trials in China

Guo-Xiang Hao1, Xiao-Xiao Yuan1, Wei Guo1

  • 1Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.

BMJ Paediatrics Open
|April 29, 2020
PubMed

Insights

Chinese paediatric drug trials have significantly increased, with most being postmarketing, single-centre, and non-blinded. Further innovation and industry support are needed for high-quality clinical research in children.

Area of Science:

  • Pharmacology and Therapeutics
  • Clinical Research
  • Pediatrics

Background:

  • Paediatric drug trials are crucial for rational drug use in children.
  • China faces challenges in conducting paediatric drug trials, with limited data on their registration status.
  • Urgent research is needed to understand the landscape of paediatric clinical trials in China.

Purpose of the Study:

  • To investigate the registration status and characteristics of paediatric drug trials in China.
  • To analyze trends and identify key features of completed and ongoing paediatric clinical trials.
  • To provide insights for improving paediatric drug research in China.

Main Methods:

  • Data were retrieved from Clinical Trial.gov and the Chinese Clinical Trial Registry up to April 22, 2019.
  • Analysis included 15 key items: registration number, funding, disease type, research stage, design, sample size, blinding, and participant age.
  • A total of 1388 paediatric drug trials registered in China were analyzed.

Main Results:

  • A steady increase in paediatric drug trials was observed, exceeding 100 annually after 2012.
  • Most trials were postmarketing (57.6%), single-centre (75.3%), interventional (83.6%), and non-blinded (84.2%).
  • Trials focused on antineoplastic agents (18.3%), anti-infectives (11.2%), and vaccines (11.1%).

Conclusions:

  • Paediatric drug trials in China have progressed significantly in recent years.
  • Encouraging innovative methods and optimizing trial designs are essential for accelerating paediatric research.
  • Stimulating pharmaceutical companies through legislation is vital for conducting high-quality paediatric clinical trials.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
130
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
148
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
170
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
194
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K